Sanofi has said it plans to start discussions about filing its oral BTK inhibitor tolebrutinib for multiple sclerosis, even though the drug only achieved its primary objective in one of three phase 3 ...
President Donald Trump’s approval rating declined one point in a Reuters/Ipsos poll released Tuesday—hours after Trump claimed he has the “highest poll numbers [he’s] ever had”—keeping his rating ...
一部の結果でアクセス不可の可能性があるため、非表示になっています。
アクセス不可の結果を表示する